Abstract
Recurrent or second primary squamous cell cancer of the head and neck in a previously irradiated field presents a therapeutic challenge in which outcomes are suboptimal and treatment is associated with significant risk of morbidity and mortality. Resection followed by risk-adapted adjuvant reirradiation, definitive reirradiation, and stereotactic body radiotherapy, all with the potential for concurrent systemic therapy, represent viable treatment strategies and can offer long-term disease control with acceptable quality of life for some of these patients. Careful patient selection based on patient-, disease-, and treatment-related factors that are considered in a multidisciplinary fashion is crucial to maximizing the therapeutic ratio of reirradiation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
